477 related articles for article (PubMed ID: 31776925)
1. An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.
Zhang J; Späth SS; Weissman SM; Katz SG
Methods Mol Biol; 2020; 2097():139-171. PubMed ID: 31776925
[TBL] [Abstract][Full Text] [Related]
2. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
3. Functional Diversity of Myeloid-Derived Suppressor Cells: The Multitasking Hydra of Cancer.
Jayakumar A; Bothwell ALM
J Immunol; 2019 Sep; 203(5):1095-1103. PubMed ID: 31427398
[TBL] [Abstract][Full Text] [Related]
4. Mathematical modeling of tumor-immune cell interactions.
Mahlbacher GE; Reihmer KC; Frieboes HB
J Theor Biol; 2019 May; 469():47-60. PubMed ID: 30836073
[TBL] [Abstract][Full Text] [Related]
5. Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy.
Chesney JA; Mitchell RA; Yaddanapudi K
J Leukoc Biol; 2017 Sep; 102(3):727-740. PubMed ID: 28546500
[TBL] [Abstract][Full Text] [Related]
6. Natural killer-dendritic cell cross-talk in cancer immunotherapy.
Kalinski P; Mailliard RB; Giermasz A; Zeh HJ; Basse P; Bartlett DL; Kirkwood JM; Lotze MT; Herberman RB
Expert Opin Biol Ther; 2005 Oct; 5(10):1303-15. PubMed ID: 16197336
[TBL] [Abstract][Full Text] [Related]
7. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy.
Wilkerson A; Kim J; Huang AY; Zhang M
Curr Top Med Chem; 2017; 17(16):1843-1857. PubMed ID: 27875974
[TBL] [Abstract][Full Text] [Related]
9. NK cell-based cancer immunotherapy: from basic biology to clinical application.
Li Y; Yin J; Li T; Huang S; Yan H; Leavenworth J; Wang X
Sci China Life Sci; 2015 Dec; 58(12):1233-45. PubMed ID: 26588912
[TBL] [Abstract][Full Text] [Related]
10. Natural killer cell-based immunotherapy: From transplantation toward targeting cancer stem cells.
Dianat-Moghadam H; Rokni M; Marofi F; Panahi Y; Yousefi M
J Cell Physiol; 2018 Jan; 234(1):259-273. PubMed ID: 30144312
[TBL] [Abstract][Full Text] [Related]
11. CD200-CD200R Pathway in the Regulation of Tumor Immune Microenvironment and Immunotherapy.
Liu JQ; Hu A; Zhu J; Yu J; Talebian F; Bai XF
Adv Exp Med Biol; 2020; 1223():155-165. PubMed ID: 32030689
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cells: the journey from puzzles in biology to treatment of cancer.
Bodduluru LN; Kasala ER; Madhana RM; Sriram CS
Cancer Lett; 2015 Feb; 357(2):454-67. PubMed ID: 25511743
[TBL] [Abstract][Full Text] [Related]
13. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel JC; Crozat K; Dalod M; Mattiuz R
Front Immunol; 2019; 10():9. PubMed ID: 30809220
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological targeting of natural killer cells for cancer immunotherapy.
Miyazato K; Hayakawa Y
Cancer Sci; 2020 Jun; 111(6):1869-1875. PubMed ID: 32301190
[TBL] [Abstract][Full Text] [Related]
15. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice.
Kozlowska AK; Kaur K; Topchyan P; Jewett A
Cancer Immunol Immunother; 2016 Jul; 65(7):835-45. PubMed ID: 27034236
[TBL] [Abstract][Full Text] [Related]
16. The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy.
Souza-Fonseca-Guimaraes F; Cursons J; Huntington ND
Trends Immunol; 2019 Feb; 40(2):142-158. PubMed ID: 30639050
[TBL] [Abstract][Full Text] [Related]
17. Interactions among myeloid regulatory cells in cancer.
Umansky V; Adema GJ; Baran J; Brandau S; Van Ginderachter JA; Hu X; Jablonska J; Mojsilovic S; Papadaki HA; Pico de Coaña Y; Santegoets KCM; Santibanez JF; Serre K; Si Y; Sieminska I; Velegraki M; Fridlender ZG
Cancer Immunol Immunother; 2019 Apr; 68(4):645-660. PubMed ID: 30003321
[TBL] [Abstract][Full Text] [Related]
18. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
Hossain F; Majumder S; Ucar DA; Rodriguez PC; Golde TE; Minter LM; Osborne BA; Miele L
Front Immunol; 2018; 9():1288. PubMed ID: 29915603
[TBL] [Abstract][Full Text] [Related]
19. Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy.
Anguille S; Smits EL; Bryant C; Van Acker HH; Goossens H; Lion E; Fromm PD; Hart DN; Van Tendeloo VF; Berneman ZN
Pharmacol Rev; 2015 Oct; 67(4):731-53. PubMed ID: 26240218
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell-derived exosomes for cancer therapy.
Pitt JM; André F; Amigorena S; Soria JC; Eggermont A; Kroemer G; Zitvogel L
J Clin Invest; 2016 Apr; 126(4):1224-32. PubMed ID: 27035813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
